Search clinical trials for: Androgen ablation therapy

Total 55619 results

Turku University Hospital

Recruiting

Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA)

Prostate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate Cancer

Finland
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
Institut Mutualiste Montsouris
University of Turin, Italy

Recruiting

EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control. (ENHANCE)

Prostate Cancer | Androgen Deprivation Therapy

France
Sidney Kimmel Comprehensive Cancer Center at Johns...

Active, not recruiting

Radiation and Androgen Ablation for Prostate Cancer

Adenocarcinoma of the Prostate

United States
University of Chicago
Janssen, LP

Suspended

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Prostate Cancer

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer (CHAARTED)

Metastatic Hormone-sensitive Prostate Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Columbia University; NYU Langone Health; Weill... and other collaborators

Active, not recruiting

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Medical College of Wisconsin

Completed

Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

Prostate Cancer

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer

Prostate Cancer
M.D. Anderson Cancer Center
Exelixis; High Impact Clinical Research Support Program

Completed

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

Prostate Cancer

United States
M.D. Anderson Cancer Center
Medivation, Inc.; Janssen Services, LLC

Completed

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Prostate Cancer

United States
University of Wisconsin, Madison
Novartis Pharmaceuticals

Completed

Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy

Prostate Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Sanofi

Completed

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer (NRR)

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Canadian Urology Research Consortium
GlaxoSmithKline

Completed

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer (AVIAS)

Prostate Cancer

Canada
Ferring Pharmaceuticals

Completed

An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer

Prostate Cancer

Belgium, Germany, Hungary, Netherlands, Romania, Russian Federation, South Africa
M.D. Anderson Cancer Center
Pfizer

Completed

Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer

Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Prostate Cancer

United States
A.O.U. San Giovanni Battista di Torino, Italy

Unknown

Androgen Ablation With or Without Docetaxel in Treating Patients With Advanced Prostate Cancer

Pain | Prostate Cancer

Italy
Ferring Pharmaceuticals

Completed

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Netherlands, Hungary, Czech Republic, Germany, Mexico, Romania, Russian Federation, Ukraine, Canada, Puerto Rico, United Kingdom
AstraZeneca

Completed

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT) (UROCOR)

Prostatic Cancer

Spain
Ferring Pharmaceuticals

Completed

A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Ferring Pharmaceuticals

Completed

Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486

Prostate Cancer

United States
Ferring Pharmaceuticals

Terminated

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Prostate Cancer

United States
Ferring Pharmaceuticals

Terminated

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

Prostate Cancer
Ferring Pharmaceuticals

Completed

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Prostate Cancer

United States, Czech Republic, Hungary, Romania, Canada
Ferring Pharmaceuticals

Withdrawn

Open-Label, Randomised Parallel-Group Study

Prostate Cancer
Ferring Pharmaceuticals

Completed

Extension Study Investigating the Long-Term Safety of Degarelix Three-Month Depots in Patients With Prostate Cancer

Prostate Cancer

Finland, Belgium, Netherlands, Russian Federation, Germany, Romania, United Kingdom, France, Montenegro, Serbia
Ferring Pharmaceuticals

Completed

A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer

Prostate Cancer

United States, Belgium, Netherlands, Canada, Russian Federation, Finland, Former Serbia and Montenegro, France, Germany, Romania, United Kingdom
Ferring Pharmaceuticals

Completed

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Prostate Cancer

United States, Canada
Main Line Health
Pfizer; Sumitomo Pharma America, Inc.

Not yet recruiting

The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

Endometriosis

United States
Peking University Third Hospital
Bayer

Not yet recruiting

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

Prostate Cancer

China
Medical University of Vienna
Lund University; Ziekenhuis Netwerk Antwerpen (ZNA); St. Antonius Hospital; Azienda... and other collaborators

Not yet recruiting

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study (OLIGOMET)

Prostate Cancer | Prostate Cancer Metastatic | Oligometastasis | Prostate Neoplasm | Oligometastatic Disease | Prostate Cancer Metastatic to Bone
The University of Hong Kong

Recruiting

MWA vs RFA for the Treatment of Moderate-sized Benign Thyroid Nodules

Ablation Therapy | Thyroid Nodule \(Benign\)

Hong Kong
NYU Langone Health

Recruiting

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
University of Miami

Recruiting

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer (OCEAN)

Prostate Cancer | Prostate Adenocarcinoma | Hormone Sensitive Prostate Cancer

United States
Mayo Clinic

Recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
Chengdu University of Traditional Chinese Medicine

Recruiting

Comparative Clinical Efficacy Between Multi-layer Bandage Pressure Therapy and Gradient Pressure Elastic Stocking Treatment After Endovenous Radiofrequency Ablation

Vascular Diseases, Peripheral | Venous Insufficiency of Leg | Varicose Veins of Lower Limb

China
Western Sydney Local Health District
National Heart Foundation, Australia; University of Sydney

Not yet recruiting

Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease (Radioablate)

Arrhythmias, Cardiac | Cardiomyopathies | Ventricular Tachycardia | Ventricular Arrythmia
Gitte Fredberg Persson MD PhD

Recruiting

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease (OLIGO-DK)

Surgery | Oligometastatic Disease | Radiotherapy | Metastases | Stereotactic Radiation | Ablation Techniques

Denmark
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients

Metastatic Prostate Cancer | Therapy, Directly Observed

China
Peking University First Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd

Recruiting

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma

Salivary Gland Neoplasm Duct

China
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
University of Washington
Washington State University

Not yet recruiting

Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 (OralT12)

Hypogonadism, Male
Pedro Barata, MD, MSc
ESSA Pharma Inc.

Not yet recruiting

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma | Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Prostate Cancer | Biochemical Recurrence

China
Roswell Park Cancer Institute

Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8

United States

Search clinical trials for: Androgen ablation therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations